An inducible RIPK3-driven necroptotic system enhances cancer cell–based immunotherapy and ensures safety
Journal of Clinical Investigation · 16.01.2025 · 135 (2)
DOI: 10.1172/jci181143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 19.11.2024. Verfasst von Kok-Siong Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Stem Cell and Translational Immunotherapy and. Hauptthemen laut MEDLINE: Receptor-Interacting Protein Serine-Threonine Kinases, Immunotherapy, Necroptosis, Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NINDS.
Abstract (Originalsprache)
Recent progress in cancer cell–based therapies has led to effective targeting and robust immune responses against cancer. However, the inherent safety risks of using live cancer cells necessitate the creation of an optimized safety switch without hindering the efficacy of immunotherapy. The existing safety switches typically induce tolerogenic cell death, potentially leading to an immunosuppressive tumor immune microenvironment (TIME), which is counterproductive to the goals of immunotherapy. Here, we developed and characterized an inducible receptor-interacting protein kinase 3–driven (RIPK3-driven) necroptotic system that serves a dual function of safety switch as well as inducer of immunogenic cell death, which in turn stimulates antitumor immune responses. We show that activation of the RIPK3 safety switch triggered immunogenic responses marked by an increased release of ATP and damage-associated molecular patterns (DAMPs). Compared with other existing safety switches, incorporating the RIPK3 system inhibited tumor growth, improved survival outcomes in tumor-bearing mice, and fostered long-term antitumor immunity. Moreover, the RIPK3 system reinvigorated the TIME by promoting DC maturation, polarizing the macrophages toward a M1 phenotype, and reducing the exhaustion of CD4 + and CD8 + T lymphocytes. Our study highlights the dual role of the RIPK3-driven necroptotic system in improving the safety and efficacy of cancer cell–based therapy, with broader implications for cellular therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Stem Cell and Translational Immunotherapy and.
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Education and Research in Biology, ENS Paris-Saclay, Université Paris-Saclay, Gif-sur-Yvette, France.
- Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA.
Förderung
- NINDS NIH HHS
- NINDS
Zitieren
APA
Chen, K. S., Manoury-Battais, S., Kanaya, N., Vogiatzi, I., Borges, P., Kruize, S. J., Chen, Y. C., Lin, L. Y., Rossignoli, F., Mendonca, N. C., & Shah, K. (2025). An inducible RIPK3-driven necroptotic system enhances cancer cell–based immunotherapy and ensures safety. Journal of Clinical Investigation, 135(2). https://doi.org/10.1172/jci181143
Vancouver
Chen KS, Manoury-Battais S, Kanaya N, Vogiatzi I, Borges P, Kruize SJ, et al. An inducible RIPK3-driven necroptotic system enhances cancer cell–based immunotherapy and ensures safety. Journal of Clinical Investigation. 2025;135(2). doi:10.1172/jci181143
BibTeX
@article{Chen2025,
author = {Chen, Kok-Siong and Manoury-Battais, Sarah and Kanaya, Nobuhiko and Vogiatzi, Ioulia and Borges, Paulo and Kruize, Sterre J and Chen, Yi-Ching and Lin, Laura Y and Rossignoli, Filippo and Mendonca, Natalia Claire and Shah, Khalid},
title = {An inducible RIPK3-driven necroptotic system enhances cancer cell–based immunotherapy and ensures safety},
journal = {Journal of Clinical Investigation},
year = {2025},
volume = {135},
number = {2},
doi = {10.1172/jci181143}
}
EUVIMED